Vigil Neuroscience (NASDAQ:VIGL) Cut to Hold at Stifel Nicolaus

Stifel Nicolaus downgraded shares of Vigil Neuroscience (NASDAQ:VIGL - Free Report) from a buy rating to a hold rating in a report released on Wednesday, MarketBeat.com reports. The firm currently has $8.00 target price on the stock, down from their prior target price of $11.00.

VIGL has been the subject of a number of other reports. Citizens Jmp lowered shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Mizuho cut shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 23rd. Citigroup downgraded shares of Vigil Neuroscience to a "market perform" rating in a report on Thursday, May 22nd. Wedbush lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and cut their price target for the stock from $13.00 to $8.00 in a research note on Thursday, May 22nd. Finally, JMP Securities reissued a "market perform" rating on shares of Vigil Neuroscience in a report on Thursday, May 22nd. Ten equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $10.80.

Vigil Neuroscience Price Performance

NASDAQ VIGL remained flat at $7.88 on Wednesday. The company had a trading volume of 1,210,695 shares, compared to its average volume of 659,578. The business has a 50-day simple moving average of $2.79 and a 200 day simple moving average of $2.44. Vigil Neuroscience has a 12 month low of $1.31 and a 12 month high of $7.95. The firm has a market cap of $367.78 million, a P/E ratio of -3.83 and a beta of 1.90.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. As a group, analysts anticipate that Vigil Neuroscience will post -2.07 EPS for the current year.

Institutional Trading of Vigil Neuroscience

Several hedge funds have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC grew its position in shares of Vigil Neuroscience by 53.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after purchasing an additional 8,358 shares in the last quarter. Jane Street Group LLC bought a new position in Vigil Neuroscience during the fourth quarter valued at approximately $83,000. Barclays PLC boosted its stake in Vigil Neuroscience by 43.6% during the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after buying an additional 19,436 shares during the last quarter. Northern Trust Corp grew its holdings in Vigil Neuroscience by 29.0% during the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after buying an additional 14,572 shares in the last quarter. Finally, Two Sigma Advisers LP increased its stake in Vigil Neuroscience by 243.8% in the 4th quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock worth $117,000 after acquiring an additional 49,000 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.